 "Suven Life receives patents in Eurasia, Japan and Mexico")
Suven Life Sciences Ltd has received three patents for its new chemical entities (NCEs) in Eurasia, Japan and Mexico. Suven Life Sciences announced on December 30, 2014, that the company was granted three product patents from Eurasia, Japan and Mexico corresponding to the NCEs for the treatment of disorders associated with neurodegenerative diseases and these patents are valid through 2029.
The granted claims of the patents include the class of selective 5-HT compounds discovered by Suven and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer’s disease, Attention deficient hyperactivity disorder (ADHD), Huntington’s disease, Parkinson and Schizophrenia.
With these new patents, Suven Life Sciences has a total of 13 granted patents from Eurasia, 12 granted patents from Japan and 17 product patents from Mexico. These granted patents are exclusive intellectual property of Suven and are achieved through the internal discovery research efforts. Products out of these inventions may be out-licensed at various phases of clinical development like at Phase-I or Phase-II.
“We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally,” said Venkat Jasti, CEO of Suven Life Sciences.
The granted claims of the patents include the class of selective 5-HT compounds discovered by Suven and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer’s disease, Attention deficient hyperactivity disorder (ADHD), Huntington’s disease, Parkinson and Schizophrenia.
With these new patents, Suven Life Sciences has a total of 13 granted patents from Eurasia, 12 granted patents from Japan and 17 product patents from Mexico. These granted patents are exclusive intellectual property of Suven and are achieved through the internal discovery research efforts. Products out of these inventions may be out-licensed at various phases of clinical development like at Phase-I or Phase-II.
“We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally,” said Venkat Jasti, CEO of Suven Life Sciences.